Please use this identifier to cite or link to this item:
Title: Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report.
Austin Authors: Lie, Gabrielle ;Weickhardt, Andrew;Kearney, Leighton G ;Lam, Que;John, Thomas ;Liew, David F L ;Arulananda, Surein
Affiliation: Cardiology
Olivia Newton-John Cancer Wellness and Research Centre
Medical Oncology
General Medicine
Cancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Heidelberg, Australia
Issue Date: Apr-2020
Publication information: Translational Lung Cancer Research 2020; 9(2): 360-365
Abstract: Malignant pleural mesothelioma (MPM) remains a deadly disease with limited therapeutic options beyond platinum/pemetrexed chemotherapy. Immune checkpoint inhibitors have demonstrated modest benefit in the second to later-line settings. An MPM patient from our institute developed myocarditis and myositis after 2 cycles of second-line nivolumab. Despite immunosuppression with corticosteroids and mycophenolate mofetil, there was ongoing rise in troponin levels which remained elevated for months. The patient developed an impressive but brief response following cessation of nivolumab. Myocarditis and myositis are rare complications of immune checkpoint inhibitors. Clinicians should be aware of these possible complications as myocarditis can result in mortality.
DOI: 10.21037/tlcr.2020.02.05
ORCID: 0000-0003-3399-5342
Journal: Translational Lung Cancer Research
PubMed URL: 32420076
ISSN: 2218-6751
Type: Journal Article
Subjects: Nivolumab
case report
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 7, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.